B of A Securities Maintains Neutral on Rhythm Pharmaceuticals, Raises Price Target to $52
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has maintained a Neutral rating on Rhythm Pharmaceuticals while raising the price target from $48 to $52.
October 14, 2024 | 5:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities has maintained a Neutral rating on Rhythm Pharmaceuticals, but increased the price target from $48 to $52, indicating a positive outlook.
The increase in the price target from $48 to $52 suggests a positive outlook for Rhythm Pharmaceuticals, which could lead to a short-term increase in stock price. However, the Neutral rating indicates that the analyst does not expect significant outperformance.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100